Detalhe da pesquisa
1.
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
N Engl J Med
; 390(16): 1467-1480, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38657244
2.
A rare KMT2A::CBL transcript in an acute monoblastic leukemia patient with an unfavorable outcome.
Mol Biol Rep
; 51(1): 561, 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643442
3.
Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.
Br J Haematol
; 202(3): 517-524, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37192741
4.
Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy.
Cytotherapy
; 25(2): 192-201, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36496302
5.
Relapsed/Refractory Peripheral T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis With UNC13D and CD27 Germline Mutations.
Cell Transplant
; 33: 9636897231221887, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38183241
6.
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies.
Exp Hematol Oncol
; 13(1): 28, 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38444007
7.
HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma.
Cell Transplant
; 32: 9636897231194265, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37667507
8.
Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study.
EClinicalMedicine
; 60: 102010, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37251628
9.
BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement.
J Immunother
; 45(1): 25-34, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34874329
10.
CAR T-cell therapies in China: rapid evolution and a bright future.
Lancet Haematol
; 9(12): e930-e941, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455608
11.
CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies.
Nat Commun
; 13(1): 5313, 2022 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36085303
12.
Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction.
Front Immunol
; 12: 627764, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33717147
13.
Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.
J Cancer
; 12(18): 5423-5431, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34405005
14.
Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy.
Bone Marrow Transplant
; 56(3): 570-580, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32943758
15.
Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome-A Wandering Road to Remission.
Front Oncol
; 11: 755584, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34868965
16.
Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse.
Front Oncol
; 11: 750218, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34790576
17.
Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma.
Front Oncol
; 11: 713577, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34422666
18.
New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.
Front Oncol
; 11: 702644, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34277448
19.
Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy.
Clin Cancer Res
; 27(23): 6384-6392, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34548316
20.
Author Correction: CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies.
Nat Commun
; 15(1): 2678, 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538577